Hua Medicine Ltd. (HK:2552)
:2552
Want to see HK:2552 full AI Analyst Report?
Top Page
Hua Medicine
(2552)
Select Model
Select Model
Rating:50Neutral
Price Target:
HK$3.50
▲(6.38% Upside)
Action:ReiteratedDate:04/25/26
The score is held back primarily by weak financial quality—ongoing operating losses and negative operating/free cash flow despite reported net profit—raising sustainability and funding concerns. Technicals are neutral-to-mixed, offering limited support. Valuation is a relative positive due to the low P/E, but it does not fully offset the cash-flow and profitability risks.
Positive Factors
Revenue Growth Momentum
Sustained revenue acceleration signals expanding product adoption and commercial traction in Hua's core diabetes franchise. Durable top-line growth supports scale for R&D and commercialization, improving the odds of reaching operating leverage over the medium term.
Negative Factors
Persistent Operating Losses
Large negative operating and EBITDA margins show the core business remains unprofitable on an operational basis. That structural loss profile requires continued external funding or significant margin improvement to sustain operations and invest in commercialization over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Momentum
Sustained revenue acceleration signals expanding product adoption and commercial traction in Hua's core diabetes franchise. Durable top-line growth supports scale for R&D and commercialization, improving the odds of reaching operating leverage over the medium term.
Read all positive factors
Hua Medicine (2552) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.27B
Dividend YieldN/A
Average Volume (3M)6.34M
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth92.87%
EPS GrowthN/A
CountryHK
Employees168
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.13
Shares Outstanding1,056,605,000
10 Day Avg. Volume6,422,209
30 Day Avg. Volume6,335,350
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.71
Price to Sales (P/S)5.69
P/FCF Ratio-45.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.16
Revenue Forecast (FY)HK$1.03B
Hua Medicine Business Overview & Revenue Model
Company Description
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and ...
How the Company Makes Money
null...
Hua Medicine Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
52
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 480.18M | 255.89M | 76.61M | 17.60M | 0.00 |
| Gross Profit | 273.10M | 124.72M | 37.37M | 7.69M | 0.00 |
| EBITDA | -109.50M | -345.36M | -167.09M | -168.06M | -309.69M |
| Net Income | 1.08B | -250.14M | -211.23M | -203.77M | -330.95M |
Balance Sheet | |||||
| Total Assets | 1.47B | 1.53B | 1.73B | 1.12B | 903.55M |
| Cash, Cash Equivalents and Short-Term Investments | 1.09B | 1.14B | 1.46B | 490.63M | 675.24M |
| Total Debt | 301.80M | 300.18M | 167.75M | 97.58M | 71.53M |
| Total Liabilities | 463.48M | 1.66B | 1.62B | 841.92M | 453.22M |
| Stockholders Equity | 1.01B | -135.47M | 101.15M | 279.58M | 450.33M |
Cash Flow | |||||
| Free Cash Flow | -59.70M | -421.83M | 879.52M | -257.58M | -339.87M |
| Operating Cash Flow | -52.15M | -417.97M | 889.37M | -230.11M | -272.98M |
| Investing Cash Flow | -654.00K | 10.04M | 8.08M | -4.75M | -68.22M |
| Financing Cash Flow | 9.10M | 83.72M | 69.07M | 21.48M | -6.13M |
Hua Medicine Technical Analysis
Positive
3.29
Price Trends
3.22
Positive
3.21
Positive
3.46
Positive
Market Momentum
0.17
Negative
62.85
Neutral
74.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2552, the sentiment is Positive. The current price of 3.29 is below the 20-day moving average (MA) of 3.45, above the 50-day MA of 3.22, and below the 200-day MA of 3.46, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 62.85 is Neutral, neither overbought nor oversold. The STOCH value of 74.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2552.
Hua Medicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$30.34B | 9.36 | 13.95% | 4.09% | 1.48% | -1.55% | |
72 Outperform | HK$226.68B | 20.40 | 16.09% | 0.97% | 22.62% | 26.23% | |
63 Neutral | HK$16.60B | 8.36 | 2.86% | 5.23% | 3.74% | -40.22% | |
58 Neutral | HK$32.42B | 3.24 | 7.91% | 2.95% | 4.66% | 20.77% | |
55 Neutral | HK$18.35B | ― | 41.38% | ― | -13.04% | 1113.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$3.27B | -9.58 | 206.86% | ― | 92.87% | ― |
* Healthcare Sector Average
HK:2552
Hua Medicine
3.37
1.15
51.80%
HK:0013
HUTCHMED (China)
21.04
-2.36
-10.09%
HK:1513
Livzon Pharmaceutical Group
27.78
2.44
9.64%
HK:3320
China Resources Pharmaceutical Group Ltd.
5.16
0.33
6.90%
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
4.81
0.52
12.12%
HK:3692
Hansoh Pharmaceutical Group Company Limited
37.38
13.20
54.59%
Hua Medicine Corporate Events
Hua Medicine Sets 2026 AGM to Approve Accounts and Renew Capital Mandates
Apr 22, 2026
Hua Medicine has called its annual general meeting for June 25, 2026, at its Shanghai headquarters, where shareholders will review the audited financial statements for the year ended December 31, 2025, and consider the re-election of three directo...
Hua Medicine Seeks Shareholder Approval for Digital-Friendly Articles Update
Apr 16, 2026
Hua Medicine plans to update its constitutional documents by replacing its third amended and restated memorandum and articles of association with a fourth version. The key change is to permit shareholder general meetings to be held as electronic o...
Hua Medicine Doubles Diabetes Drug Revenue and Secures Hong Kong Approval for Dorzagliatin
Mar 26, 2026
Hua Medicine reported rapid commercial growth in 2025 as it took over marketing and sales of its first-in-class antidiabetes drug dorzagliatin in mainland China, selling over four million packs and nearly doubling revenue to RMB492.9 million while...
Hua Medicine Reshuffles Company Secretary and Authorised Representative Roles
Mar 26, 2026
Hua Medicine has announced a change in its corporate secretarial leadership, with Ms. Yuen Wing Yan Winnie resigning as company secretary and authorised representative effective March 26, 2026, without any disagreement with the board or issues req...
Hua Medicine Relocates Hong Kong Principal Place of Business
Mar 23, 2026
Hua Medicine has announced that it will relocate its principal place of business in Hong Kong from Unit 506, Hang Seng Wanchai Building, 200 Hennessy Road, Wanchai, to Suite 1701, 8 Queen’s Road East, Wanchai, effective March 23, 2026. The m...
Hua Medicine Sets March 26 Board Meeting to Approve 2025 Results
Mar 16, 2026
Hua Medicine has scheduled a board meeting for March 26, 2026 to review and approve the group’s audited final results for the financial year ended December 31, 2025. At the same meeting, directors will also consider whether to recommend a fi...
Hua Medicine Wins Hong Kong Approval for Pioneering Diabetes Drug Dorzagliatin
Mar 3, 2026
Hua Medicine announced that its first-in-class glucokinase activator dorzagliatin has been approved for marketing in Hong Kong for the treatment of Type 2 diabetes in adults, becoming the first innovative primary care drug cleared under the city&#...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.